The latest research developments, clinical trial updates, and regulatory news from the peptide science community.
BPC-157 and TB-500 are the two most-studied healing peptides in preclinical research. We examine why combining them makes mechanistic sense, what the limited combination data shows, and how the two compounds complement each other.
TB-500's actin-sequestering mechanism distinguishes it from growth factor-based repair peptides. We review the preclinical evidence base and what the LEMS/ABS pathway data tells researchers about systemic healing properties.
A recently published study in Peptides examined BPC-157's effects on gut-brain signalling pathways in rodent models, adding to the growing body of preclinical data on this stable gastric pentadecapeptide.
All content is for scientific and educational purposes only. Research peptides are for laboratory use only and not intended for human consumption or therapeutic application.
